Aptose Biosciences Files Routine 8-K for Disclosure Compliance
Ticker: APTOF · Form: 8-K · Filed: Jan 26, 2024 · CIK: 882361
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, compliance
TL;DR
**Aptose Biosciences filed a routine 8-K, no major news.**
AI Summary
Aptose Biosciences Inc. filed an 8-K on January 26, 2024, indicating a routine filing for Regulation FD Disclosure and Financial Statements and Exhibits. This filing, under SEC File Number 001-32001, primarily serves to update the public record and does not contain specific new financial or operational news. For investors, this means there's no immediate new information that would drastically alter their investment thesis, but it confirms the company's ongoing compliance with SEC reporting requirements.
Why It Matters
This filing is a standard compliance update, showing Aptose Biosciences Inc. is meeting its regulatory obligations, which is important for maintaining investor confidence in its transparency.
Risk Assessment
Risk Level: low — This 8-K is a standard regulatory filing with no new material information, posing minimal risk.
Analyst Insight
A smart investor would note this as a routine compliance filing and look for other, more substantive filings (like 10-K, 10-Q, or other 8-Ks with specific news items) for actionable information regarding Aptose Biosciences Inc.
Key Players & Entities
- Aptose Biosciences Inc. (company) — the registrant filing the 8-K
- 001-32001 (dollar_amount) — SEC File Number
- January 26, 2024 (person) — Date of Report
- Canada (company) — State or Other Jurisdiction of Incorporation
- 251 Consumers Road, Suite 1105 Toronto, Ontario M2J 4R3 Canada (company) — Address of Principal Executive Offices
- 647-479-9828 (dollar_amount) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Aptose Biosciences Inc.?
This 8-K filing by Aptose Biosciences Inc. is for Regulation FD Disclosure and Financial Statements and Exhibits, as indicated in the 'ITEM INFORMATION' section of the filing.
When was this 8-K report filed?
The Date of Report (Date of earliest event reported) for this 8-K is January 26, 2024, as stated in the filing.
What is Aptose Biosciences Inc.'s SEC File Number?
Aptose Biosciences Inc.'s SEC File Number is 001-32001, as listed under 'Commission File Number' in the filing.
Where are Aptose Biosciences Inc.'s principal executive offices located?
The principal executive offices of Aptose Biosciences Inc. are located at 251 Consumers Road, Suite 1105, Toronto, Ontario M2J 4R3, Canada, according to the filing.
What is the registrant's telephone number?
The registrant's telephone number, including area code, is (647) 479-9828, as provided in the filing.
Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2024-01-26 08:00:14
Filing Documents
- f8k_012624.htm (8-K) — 14KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-000425.txt ( ) — 222KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_012624_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On January 26, 2024, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. 99.1 Press Release dated January 26, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: January 26, 2024 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. Chairman, President, and Chief Executive Officer